Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/28/2025

Management of Diffuse Hepatic Steatosis

Initial Diagnostic Workup

  • The European Association for the Study of the Liver recommends verifying the presence of at least one cardiometabolic risk factor to classify this as metabolic dysfunction-associated steatotic liver disease (MASLD) 1, 2
  • The American Association for the Study of Liver Diseases suggests obtaining detailed alcohol history: consumption must be <30 g/day in men and <20 g/day in women to confirm MASLD rather than alcohol-related liver disease 1, 2
  • The American Gastroenterological Association recommends excluding secondary causes: review medications, screen for hepatitis B/C, and consider rare causes (Wilson disease, autoimmune hepatitis, α1-antitrypsin deficiency, hemochromatosis) 4

Risk Stratification for Fibrosis

  • The American Association for the Study of Liver Diseases recommends calculating FIB-4 score as the first-tier non-invasive assessment to stratify patients: low risk (FIB-4 <1.3), intermediate risk (FIB-4 1.3-2.67), and high risk (FIB-4 >2.67) 1, 2

Treatment Approach

  • The European Association for the Study of the Liver suggests implementing lifestyle modifications as first-line therapy for all patients, including a hypocaloric diet with 500-1000 kcal daily deficit and 150-300 minutes/week of moderate-intensity exercise 6, 7
  • The American Heart Association recommends managing cardiometabolic comorbidities, including type 2 diabetes with GLP-1 receptor agonists or SGLT2 inhibitors, and dyslipidemia with statins 1, 6

Pharmacologic Treatment for Advanced Disease

  • The American Association for the Study of Liver Diseases recommends reserving pharmacotherapy for patients with biopsy-proven steatohepatitis and significant fibrosis (≥F2), and considering treatment options such as resmetirom, vitamin E, or pioglitazone 1, 7

Special Considerations

  • The American Gastroenterological Association suggests considering bariatric surgery in appropriate individuals with clinically significant fibrosis and obesity with comorbidities 1, 7
  • The European Association for the Study of the Liver recommends cirrhosis management, including HCC surveillance, screening for gastroesophageal varices, and nutritional counseling 1, 3